Project Grant R00HL177830
Award Date
3/17/25
Completion Date
2/29/28
Dollars Obligated
$445K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease.
The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $756,875 from January 1, 2025 to December 31, 2029 to the University of Cincinnati. The funding will support research to investigate the molecular mechanisms by which neutrophil extracellular traps (NETs) contribute to airway damage and infection in mucoobstructive lung diseases such as cystic fibrosis. The key research...
This $637,526 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease.
The researchers at Duke University will investigate how characteristics of sickle RBCs, such as phosphatidylserine exposure and adhesion receptor activation, directly induce specific...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify the role of myeloid-derived suppressor cells (MDSC) in the immune response of children with severe viral lower respiratory tract infections (LRTI). The $180,199 award to the Research Institute at Nationwide Children's Hospital aims to characterize changes in MDSC and T cell populations in pediatric patients with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $163,080 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Ann & Robert H. Lurie Children's Hospital of Chicago. The grant, which runs from September 1, 2024 to August 31, 2029, will fund a multidimensional analysis of the regulatory T cell response in children with severe viral pneumonia. The research aims to determine whether juvenile regulatory T cells have impaired reparative functions during severe...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $145,910 to The Children's Hospital of Philadelphia (CHOP) to conduct a prospective observational study on myocardial dysfunction and inflammation in 200 critically ill children after cardiac arrest. The study will utilize advanced echocardiographic imaging and a customized panel of circulating biomarkers to assess these...
This $3,116,931 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to define the neutrophil pathobiology driving Long COVID in children. The award recipient, The General Hospital Corporation (doing business as Massachusetts General Hospital), will use single-cell RNA sequencing and microfluidics to characterize the neutrophil activation profiles and functionality in Long COVID patients,...
This federal Project Grant award of $827,753.90 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of thiol isomerases, particularly protein disulfide isomerase (PDI), in promoting redox-sensitive vaso-occlusion in sickle cell disease. The research aims to mechanistically examine how PDI senses and responds to the redox environment in sickle cell disease to catalyze electron transfers via cysteine...
This $1,276,908 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports continued research on the mechanisms of disease in von Willebrand disease (VWD) and sickle cell disease (SCD). The research aims to investigate the impact of VWF cleavage fragments on hemostasis, as well as the role of oxidation-induced changes to lipids in the sickle erythrocyte membrane and plasma lipoproteins in the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totaling $844,386 will support research to define the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The project aims to: 1) profile 300 CHILD lung biopsy samples to identify patient clusters with similar molecular profiles and assess their clinical significance; 2) analyze whole exome sequence data from...